Is PRAX or PHVS more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Pharvaris N/A -67.56% -61.13%

Does the media prefer PRAX or PHVS?

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Pharvaris. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 4 mentions for Pharvaris. Praxis Precision Medicines' average media sentiment score of 0.82 beat Pharvaris' score of 0.69 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or PHVS more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Pharvaris N/A -67.56% -61.13%

Does the media favor SYRE or PHVS?

In the previous week, Spyre Therapeutics had 3 more articles in the media than Pharvaris. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Spyre Therapeutics' score of 0.54 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TGTX or PHVS?

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $700.35M 11.86 $447.18M $2.86 18.97 Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is TGTX or PHVS more profitable?

TG Therapeutics has a net margin of 65.95% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Pharvaris N/A -67.56% -61.13%

Does the media favor TGTX or PHVS?

In the previous week, Pharvaris had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Pharvaris and 3 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.14 beat Pharvaris' score of 0.69 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PHVS or APGE?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A

Is PHVS or APGE more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Apogee Therapeutics N/A -32.64% -31.25%

Does the media favor PHVS or APGE?

In the previous week, Apogee Therapeutics had 40 more articles in the media than Pharvaris. MarketBeat recorded 44 mentions for Apogee Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Apogee Therapeutics' score of 0.18 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 11 Very Positive mention(s) 7 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYMR or PHVS?

In the previous week, Kymera Therapeutics had 32 more articles in the media than Pharvaris. MarketBeat recorded 36 mentions for Kymera Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Kymera Therapeutics' score of 0.07 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pharvaris (PHVS) Competitors

$33.78 +0.49 (+1.46%)

As of 10:22 AM Eastern

Compare

PHVS vs. PRAX, SYRE, TGTX, APGE, and KYMR

Should you buy Pharvaris stock or one of its competitors? MarketBeat compares Pharvaris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharvaris include Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Pharvaris compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market.

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Pharvaris. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 4 mentions for Pharvaris. Praxis Precision Medicines' average media sentiment score of 0.82 beat Pharvaris' score of 0.69 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines' return on equity of -43.02% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Pharvaris	N/A	-67.56%	-61.13%

Pharvaris has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,080.81	-$303.27M	-$13.37	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Praxis Precision Medicines presently has a consensus target price of $566.21, suggesting a potential upside of 70.83%. Pharvaris has a consensus target price of $49.64, suggesting a potential upside of 46.92%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Praxis Precision Medicines beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Pharvaris. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Spyre Therapeutics' score of 0.54 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics' return on equity of -42.88% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Pharvaris	N/A	-67.56%	-61.13%

Spyre Therapeutics has higher revenue and earnings than Pharvaris. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,736.69	-$155.20M	-$2.08	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Spyre Therapeutics presently has a consensus target price of $95.83, suggesting a potential upside of 7.03%. Pharvaris has a consensus target price of $49.64, suggesting a potential upside of 46.92%. Given Pharvaris' higher probable upside, analysts plainly believe Pharvaris is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Spyre Therapeutics beats Pharvaris on 11 of the 14 factors compared between the two stocks.

How does Pharvaris compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	11.86	$447.18M	$2.86	18.97
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

In the previous week, Pharvaris had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Pharvaris and 3 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.14 beat Pharvaris' score of 0.69 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Pharvaris	N/A	-67.56%	-61.13%

TG Therapeutics currently has a consensus price target of $58.60, indicating a potential upside of 8.00%. Pharvaris has a consensus price target of $49.64, indicating a potential upside of 46.92%. Given Pharvaris' higher probable upside, analysts plainly believe Pharvaris is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

TG Therapeutics beats Pharvaris on 12 of the 16 factors compared between the two stocks.

How does Pharvaris compare to Apogee Therapeutics?

Pharvaris (NASDAQ:PHVS) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

79.0% of Apogee Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Apogee Therapeutics had 40 more articles in the media than Pharvaris. MarketBeat recorded 44 mentions for Apogee Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Apogee Therapeutics' score of 0.18 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	11 Very Positive mention(s)	7 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Pharvaris has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Apogee Therapeutics' return on equity of -32.64% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Pharvaris currently has a consensus price target of $49.64, suggesting a potential upside of 46.92%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 8.61%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

Pharvaris and Apogee Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Pharvaris has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	245.64	-$311.35M	-$3.57	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Kymera Therapeutics presently has a consensus price target of $118.18, suggesting a potential upside of 0.94%. Pharvaris has a consensus price target of $49.64, suggesting a potential upside of 46.92%. Given Pharvaris' higher probable upside, analysts plainly believe Pharvaris is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market.

In the previous week, Kymera Therapeutics had 32 more articles in the media than Pharvaris. MarketBeat recorded 36 mentions for Kymera Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.69 beat Kymera Therapeutics' score of 0.07 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Pharvaris	N/A	-67.56%	-61.13%

Summary

Kymera Therapeutics beats Pharvaris on 8 of the 14 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.22B	$3.61B	$6.78B	$12.10B
Dividend Yield	N/A	2.27%	2.68%	5.90%
P/E Ratio	-10.65	21.62	25.91	23.95
Price / Sales	N/A	342.75	554.49	99.09
Price / Cash	N/A	134.91	46.33	53.91
Price / Book	7.17	8.16	10.61	6.31
Net Income	-$198.79M	$23.91M	$3.57B	$337.22M
7 Day Performance	3.00%	7.03%	2.85%	-0.91%
1 Month Performance	13.07%	5.47%	1.96%	-0.32%
1 Year Performance	88.74%	60.98%	32.50%	26.19%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.4233 of 5 stars	$33.79 +1.5%	$49.64 +46.9%	+89.6%	$2.22B	N/A	N/A	30	Analyst Forecast
PRAX Praxis Precision Medicines	3.3466 of 5 stars	$305.37 +0.7%	$566.21 +85.4%	+656.7%	$8.51B	$8.55M	N/A	110	Gap Up
SYRE Spyre Therapeutics	1.8354 of 5 stars	$97.05 -3.3%	$95.83 -1.3%	+464.1%	$8.43B	N/A	N/A	73	Analyst Forecast Insider Trade Gap Down High Trading Volume
TGTX TG Therapeutics	3.1505 of 5 stars	$53.94 -0.8%	$58.60 +8.6%	+43.9%	$8.26B	$700.35M	18.86	290	Positive News
APGE Apogee Therapeutics	1.42 of 5 stars	$132.88 +0.2%	$119.67 -9.9%	+208.6%	$8.23B	N/A	N/A	91	Analyst Downgrade Insider Trade Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, SYRE, TGTX, APGE, and KYMR

How does Pharvaris compare to Praxis Precision Medicines?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Summary

How does Pharvaris compare to TG Therapeutics?

Summary

How does Pharvaris compare to Apogee Therapeutics?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, SYRE, TGTX, APGE, and KYMR

How does Pharvaris compare to Praxis Precision Medicines?

Do insiders & institutionals hold more shares of PRAX or PHVS?

Which has more volatility & risk, PRAX or PHVS?

Does the media prefer PRAX or PHVS?

Is PRAX or PHVS more profitable?

Which has stronger valuation and earnings, PRAX or PHVS?

Do analysts recommend PRAX or PHVS?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Which has more risk & volatility, SYRE or PHVS?

Does the media favor SYRE or PHVS?

Is SYRE or PHVS more profitable?

Which has preferable valuation & earnings, SYRE or PHVS?

Do analysts recommend SYRE or PHVS?

Do institutionals & insiders hold more shares of SYRE or PHVS?

Summary

How does Pharvaris compare to TG Therapeutics?

Do institutionals & insiders have more ownership in TGTX or PHVS?

Which has more volatility & risk, TGTX or PHVS?

Which has better valuation and earnings, TGTX or PHVS?

Does the media favor TGTX or PHVS?

Is TGTX or PHVS more profitable?

Do analysts rate TGTX or PHVS?

Summary

How does Pharvaris compare to Apogee Therapeutics?

Do institutionals & insiders hold more shares of PHVS or APGE?

Does the media favor PHVS or APGE?

Which has preferable earnings & valuation, PHVS or APGE?

Which has more volatility & risk, PHVS or APGE?

Is PHVS or APGE more profitable?

Do analysts recommend PHVS or APGE?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Which has stronger valuation & earnings, KYMR or PHVS?

Do analysts rate KYMR or PHVS?

Which has more risk & volatility, KYMR or PHVS?

Does the media refer more to KYMR or PHVS?

Is KYMR or PHVS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools